Starting treatment on the day of HIV diagnosis improves retention and viral suppression, Haiti study shows

Image from presentation by Dr Serena Koenig.
Keith Alcorn
Published: 21 July 2016

Interventions to improve linkage to care and retention in treatment which speed up the start of treatment or provide intensive support to people before starting treatment produce better retention in care than standard practices, researchers reported at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa, on Wednesday.

Starting HIV treatment on the day of diagnosis resulted in significantly better outcomes for people in Haiti, while a package of interventions including accelerated antiretroviral therapy (ART), CD4 counts at diagnosis and intensive support delivered in Swaziland resulted in significantly better linkage to care and retention after one year on ART, the studies showed.

A study conducted in San Francisco has shown that same-day treatment initiation was acceptable to people and succeeded in retaining them in care. There is still little information about the practicalities of same-day treatment initiation in low and middle-income settings.

Haiti: Same-day ART initiation

A study conducted in Haiti which tested the impact of same-day treatment initiation on the rate of ART initiation and retention in care found that same-day treatment initiation resulted in significantly higher rates of initiation and retention.

Same-day treatment initiation has been proposed as a way of reducing the loss of patients between HIV diagnosis and ART initiation. People diagnosed with advanced HIV disease are at high risk of illness or death if they become lost to follow-up or delay starting treatment, and untreated people may pass on HIV to partners.

Same-day initiation is also designed to tackle the psychological ill-effects of an HIV diagnosis, which may also contribute to patient loss before treatment can be started.

“With standard testing protocols people are sent away with bad news. Our hypothesis was that if we rolled out the red carpet on that very challenging first day, we would give hope,” said study investigator Dr Serena Koenig of Brigham & Women’s Hospital, Boston.

The randomised study was conducted at the GHESKIO research centre and clinic in Port-au-Prince, Haiti. Researchers recruited individuals who tested positive for HIV and who had WHO (World Health Organization) stage 1 or 2 disease and a CD4 cell count below 500 cells/mm3. The study excluded people with chest X-rays suggestive of TB or pneumonia, to give more time for investigation, and also excluded anyone who displayed lack of readiness for treatment on an ART readiness questionnaire.

The study randomised 762 participants to receive either the existing standard of care (ART initiation after a third follow-up visit at day 21 post-diagnosis) (n = 384) or same-day ART initiation (n = 378). The analysis comprised 564 people with at least 12 months of follow-up (n = 564). All study participants received CD4 counts, an ART readiness questionnaire, multiple clinic and counselling visits in the first month, monthly visits thereafter, community health worker follow-up in the case of missed visits, and USD1.70 per visit in transport subsidy. The only difference between the study arms was the time of treatment initiation.

The primary outcome measured in the study was the proportion of people in each arm retained in care with viral load below 50 copies/ml at the 12-month study visit. After 12 months, 54% of the same-day ART group remained in care with viral load < 50 copies/ml compared to 42% of the standard-of-care group (p = 0.004), and were around 75% more likely to have a viral load < 50 copies/ml (adjusted odds ratio 1.76, 95% CI 1.24-2.49, p = 0.002). People in the standard-of-care group were significantly less likely to be alive and in care after 12 months (71% vs 80%, p = 0.007).

When the results were compared with a cascade of care reported from South Africa by Sydney Rosen and colleagues in 2011, the effects of the intervention on retention in care were pronounced. Whereas only 59% of people diagnosed ever completed the CD4 count stage in the South African study (receiving the CD4 result), 100% of people in the same-day group received a CD4 result. Similarly, only 68% of those who went through CD4 staging started ART in the South African study, compared to 100% of same-day ART patients in Haiti, and after 12 months only 37% of those originally diagnosed in the South African study were on ART, compared to 80% of the same-day ART patients in Haiti.

The study showed that same-day ART initiation is feasible in Haiti and results in improved retention in care and virologic suppression, as well as providing people with a sense of hope, optimism and connectedness to health care providers, Dr Koenig concluded.

However, it is worth noting that around one-third of people screened for enrollment in this study were deemed not ready to start treatment after undergoing a standardised questionnaire on readiness for treatment, indicating that same-day treatment is not suitable for everyone and that a substantial minority of people will need more preparation and support. The finding also indicates the importance of asking people about their readiness for treatment and of addressing barriers to starting treatment before dispensing pills, rather than waiting to address problems of retention in care or non-adherence when lack of readiness translates into subsequent difficulties.

Swaziland: Link4Health

The Link4Health cluster-randomised trial was designed to test the impact of a combination of interventions on linkage to care one month after diagnosis and retention in care 12 months after diagnosis.

Ten clusters of affiliated HIV care facilities in Swaziland were randomised either to receive the existing standard of care or to receive a combination of interventions consisting of:

  • Point of care CD4 cell count testing at the time of diagnosis
  • Accelerated antiretroviral treatment initiation for people diagnosed with a CD4 cell count below 350 cells/mm3
  • Mobile phone appointment reminders
  • Health education and a basic care package that included household soap, toothpaste and other items
  • Non-cash financial incentive consisting of $8 in pre-paid mobile phone cards given at months 6 and 12.

The study enrolled 2201 participants (59% women) from August 2013 to November 2014 and followed them for at least one year. The primary study outcome was linkage to care within one month of HIV diagnosis, and retention in care (HIV clinic visit within 12 months) (a composite outcome). ART initiation was measured as a secondary outcome.

The study population was 59% female with a median age of 32 years. Eighty per cent were diagnosed at a voluntary counselling and testing site, and 20% through provider-initiated counselling and testing.

Intention-to-treat analysis showed significantly higher linkage and retention in the combination-intervention arm.

 

Combination intervention (n = 1036)

Standard of care

(n = 932)

Risk

1-month linkage to care

92%

83%

1.10 (95% CI 1.36-1.60, p<0.001)

12-month retention in care

65%

45%

1.45, 95% CI 1.34-1.56, p<0.001)

Retained until ART eligible

76%

65%

P=0.04

Initiated ART ever

65%

58%

P=0.13

Mortality prior to ART initiation

1%

2%

RR 0. 44, 95% CI 0.21-0.91, p=0.02)

Overall

64%

43%

1.48 (95% CI 1.36-1.60, p<0.001)

The study found no significant difference in the effectiveness of the combination intervention according to age, sex, distance to clinic or clinic type.

References

Koenig S et al. Same-day HIV testing and antiretroviral therapy initiation results in higher rates of treatment initiation and retention in care. 21st International AIDS Conference, Durban, abstract WEAE0202, 2016.

View the abstract on the conference website.

Download the presentation slides from the conference website.

Watch the webcast of this presentation on YouTube.

McNairy M et al. LINK4HEALTH: a cluster-randomized controlled trial evaluating the effectiveness of a combination strategy for linkage to and retention in HIV care in Swaziland. 21st International AIDS Conference, Durban, abstract WEAE0206LB, 2016.

View the abstract on the conference website.

Download the presentation slides from the conference website.

Watch the webcast of this presentation on YouTube.



NAM’s news coverage of the International AIDS Conference has been made possible thanks to support from Merck & Co. NAM's wider conference news reporting services have been supported by Gilead, Janssen and ViiV Healthcare.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.